This observation has prompted the development of dedicated pumps for intraperitoneal (IP) insulin delivery that provide a more physiological way to optimize glycemic control and prevent peripheral hyperinsulinemia (Fig. 1, bottom panel). The gene discussed is INS; the disease is hyperinsulinism.